文章：

胶质母细胞瘤中的低分割放疗：姑息性、根治性与探索性应用综述

Hypofractionation in Glioblastoma: An Overview of Palliative, Definitive, and Exploratory Uses

原文发布日期：29 November 2023

DOI: 10.3390/cancers15235650

类型: Article

开放获取: 是

英文摘要：

Glioblastoma (GBM) is the most common primary brain malignancy in adults, and its incidence is increasing worldwide. Its prognosis remains limited despite recent imaging and therapeutic advances. The current standard of care is maximal safe resection followed by conventionally fractionated radiotherapy with concurrent and adjuvant temozolomide (TMZ), with or without tumor-treating fields (TTF). However, hypofractionated radiotherapy (HFRT) has also been utilized for a variety of reasons. It is an established treatment option in the palliative setting, where shortened treatment duration can positively impact the overall quality of life for older patients or those with additional health or socioeconomic considerations. HFRT, and in particular stereotactic radiosurgery (SRS), has also been explored in both the pre- and post-operative setting for newly diagnosed and recurrent diseases. In this review, we summarize the ways in which HFRT has been utilized in the GBM patient population and its evolving role in the experimental space. We also provide commentary on scenarios in which HFRT may be indicated, as well as guidance on dose and fractionation regimens informed by our institutional experience.

摘要翻译： 

胶质母细胞瘤（GBM）是成人中最常见的原发性脑部恶性肿瘤，其全球发病率正持续上升。尽管近年来影像学与治疗手段有所进展，该疾病的预后仍不乐观。当前标准治疗方案为最大范围安全切除术后，联合常规分割放疗与同步及辅助替莫唑胺（TMZ）化疗，并可选择性联合肿瘤治疗电场（TTF）。然而，大分割放疗（HFRT）也因多种原因被应用于临床实践。在姑息治疗领域，HFRT已成为成熟治疗选择——缩短疗程对老年患者或存在其他健康问题及社会经济因素的患者整体生活质量具有积极影响。对于新诊断及复发性病例，大分割放疗（特别是立体定向放射外科SRS）在术前与术后场景中的应用价值也得到探索。本文综述了HFRT在GBM患者群体中的应用模式及其在实验研究领域的发展动态，同时结合本机构临床经验，对HFRT的适用场景、剂量与分割方案选择提供指导性建议。

原文链接：

Hypofractionation in Glioblastoma: An Overview of Palliative, Definitive, and Exploratory Uses